Unicycive therapeutics, inc.UNCY.US Overview

US StockHealthcare

(No presentation for UNCY)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

UNCY Overall Performance

UNCY AI Analysis & Strategy

UNCY Recent Performance

4.07%

Unicycive therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

UNCY PowerScanner

UNCY Key Information

UNCY Valuation Metrics

UNCY Earnings Table

UNCY Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.